{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:36:17Z","timestamp":1787060177960,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Recurrences after LDR brachytherapy are known for prostate cancer. Second lines of treatment generally include surgery, cryotherapy, and androgen deprivation therapy. Re-irradiation is seldom prescribed as a treatment modality. Stereotactic ablative body radiotherapy (SABR) is an upcoming and accepted modality for low- and intermediate-risk prostate cancer. It offers conformity while delivering a high dose of radiation and limits the dose to the normal structure surrounding the target organ. In conjunction with other imaging modalities such as MRI and PET scans, accurate treatment delivery to the planning target volume is possible. SABR has not been documented as an alternative for a local recurrence or a relapse of prostate cancer. A 63-year-old male presented with urgency and poor urine flow. His PSA was 9.6 ng\/dL, and his biopsy was indicative of adenocarcinoma prostate. He underwent\n                    <jats:sup>125<\/jats:sup>\n                    I brachytherapy, and his PSA after the procedure was 3.3 ng\/dL. He underwent imaging and biopsy again in view of rising PSA levels (3.8 ng\/dL and 8 ng\/dL in two successive tests), and it showed a lesion in the prostate that was indicative of a recurrence. He was subsequently taken up for SABR to the prostate. After the bladder and rectal protocol, the patient was immobilized and a planning CT scan was obtained. The recent PET-CT scan and MRI images were fused with the simulation CT, and the lesion and the organs at risk were marked. The patient received 25 Gy in five fractions on alternate days. There was a near-complete reduction in the size of the prostate lesion that was noted in the PET-CT scan done for response assessment. PSA levels reduced to 0.28 ng\/dL after 1 month of receiving radiotherapy, and his latest levels were 0.021 ng\/dL. The patient had no early or late grade 2 or greater GI and GU toxicities. Salvage SABR is a feasible option in locally recurrent prostate cancer as a form of re-irradiation in selected cases.\n                  <\/jats:p>","DOI":"10.4103\/jcrt.jcrt_564_23","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T16:20:32Z","timestamp":1743697232000},"page":"270-274","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Salvage SABR for a locally recurrent prostate cancer post 125I seed brachytherapy and ADT failure"],"prefix":"10.4103","volume":"21","author":[{"given":"Bhooshan","family":"Zade","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Ruby Hall Clinic, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrushab","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ruby Hall Clinic, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathiya Narayanan Kumaraswamy","family":"Vatyam","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ruby Hall Clinic, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"Holla","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ruby Hall Clinic, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"341","DOI":"10.21037\/tau.2017.12.15","article-title":"Low dose rate prostate brachytherapy","volume":"7","author":"Stish","year":"2018","journal-title":"Transl Androl Urol"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00066-020-01742-5","article-title":"Biochemical control after adjuvant radiation therapy for prostate cancer: A unicentric, retrospective analysis","volume":"197","author":"Zaharie","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1590\/s1677-5538.ibju.2018.0484","article-title":"The role and importance of SBRT in prostate cancer","volume":"44","author":"Cihan","year":"2018","journal-title":"Int Braz J Urol"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate stereotactic body radiation therapy: An overview of toxicity and dose response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-20250403","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1590\/s1677-5538.ibju.2018.0142","article-title":"Prostate brachytherapy with iodine-125 seeds: Analysis of a single institutional cohort","volume":"45","author":"Leite","year":"2019","journal-title":"Int Braz J Urol"},{"key":"R10-20250403","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.radonc.2014.07.006","article-title":"Patterns of failure after iodine-125 seed implantation for prostate cancer","volume":"112","author":"Lamb","year":"2014","journal-title":"Radiother Oncol"},{"key":"R11-20250403","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13014-015-0349-0","article-title":"Iodine-125 seed brachytherapy for early stage prostate cancer: A single-institution review","volume":"10","author":"Zuber","year":"2015","journal-title":"Radiat Oncol"},{"key":"R12-20250403","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bju.14768","article-title":"Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: Updated results from a phase III randomised trial","volume":"125","author":"Sargos","year":"2020","journal-title":"BJU Int"},{"key":"R13-20250403","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdp554","article-title":"Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy","volume":"21","author":"Heyns","year":"2010","journal-title":"Ann Oncol"},{"key":"R14-20250403","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/cam4.594","article-title":"Scandinavian Prostate Cancer Group (SPCG) Trial No. 5. Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases","volume":"5","author":"Varenhorst","year":"2016","journal-title":"Cancer Med"},{"issue":"(Suppl 2)","key":"R15-20250403","first-page":"S12","article-title":"Treatment options after failure of radiation therapy-A review","volume":"4","author":"Rukstalis","year":"2002","journal-title":"Rev Urol"},{"key":"R16-20250403","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jama.2017.1704","article-title":"Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years","volume":"317","author":"Barocas","year":"2017","journal-title":"JAMA"},{"key":"R17-20250403","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-20250403","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.ju.0000132136.95221.63","article-title":"Post-brachytherapy transurethral resection of the prostate in patients with localized prostate cancer","volume":"172","author":"Flam","year":"2004","journal-title":"J Urol"},{"key":"R19-20250403","doi-asserted-by":"crossref","first-page":"102176","DOI":"10.1016\/j.ctrv.2021.102176","article-title":"Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)","volume":"95","author":"Munoz","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R20-20250403","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3390\/cancers14133187","article-title":"Re-irradiation of locally recurrent prostate cancer with Cyberknife\u00aesystem or volumetric modulated arc therapy (VMAT) and IGRT-Clarity\u00ae: Outcomes, toxicities and dosimetric evaluation","volume":"14","author":"Di Franco","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R21-20250403","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2967\/jnumed.119.228320","article-title":"Multimodality imaging of prostate cancer","volume":"60","author":"Ghafoor","year":"2019","journal-title":"J Nucl Med"},{"key":"R22-20250403","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/0970-1591.159606","article-title":"Multiparametric-MRI in diagnosis of prostate cancer","volume":"31","author":"Ghai","year":"2015","journal-title":"Indian J Urol"},{"key":"R23-20250403","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-based [(18) F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imaging Biol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_564_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:56Z","timestamp":1786647596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_564_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_564_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2023-03-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}